Clinical data managers who spent careers writing queries by hand are now watching AI draft them automatically, and the shift is moving faster than most trial teams expected. The eClinical Solutions panel on AI in data management convenes specifically to work through what that change means in practice: how AI is reshaping data review and interpretation, and what expertise human managers still need to bring that systems cannot replace.
The commercial pressure behind this conversation is real. The EDC market was valued at $3.2 billion in 2024 and is projected to reach $7.1 billion by 2030, an 8.5% annual growth rate driven partly by vendor investment in AI-assisted data cleaning and risk-based monitoring. When that much money is flowing into automation tools, the question for anyone running a clinical data team is not whether AI will change the role but which parts of the job it changes first.
The panel draws leaders from across the biotech and clinical data space to share different perspectives, which is the more useful format for a topic where vendor claims about AI capabilities routinely outpace what actually ships. Major EDC platforms have begun incorporating AI features aimed at automating repetitive configuration tasks, but how those features hold up against messy real-world trial data is a different question than what a product sheet describes. Human review of flagged anomalies, protocol deviations, and cross-site inconsistencies still requires judgment that depends on experience with how data actually breaks in practice.
Regulatory framing is also shifting. The FDA’s 2024 final guidance on AI-enabled device software introduced Predetermined Change Control Plans, which let manufacturers pre-specify at authorization the types of changes an AI system can make autonomously. That framework has direct implications for how clinical data systems document and validate AI-generated outputs, and Understanding where AI outputs require human validation is a practical reason to engage with this kind of panel discussion.
Source link: https://www.eclinicalsol.com/event/evolution-of-data-management-fueled-by-ai/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
